Asia-Pacific journal of clinical oncology最新文献

{"title":"Effectiveness of Neoadjuvant Chemotherapy With Docetaxel, Cisplatin, and S-1 for Locoregionally Advanced Gastric Adenocarcinoma: Findings From a University Hospital in Vietnam","authors":"Tho Vinh Tran,&nbsp;Truc Thanh Thai,&nbsp;Loi Ngoc La,&nbsp;Ngon Van Dinh,&nbsp;Vo Duy Long,&nbsp;Bac Hoang Nguyen","doi":"10.1111/ajco.70039","DOIUrl":"10.1111/ajco.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate treatment results of a neoadjuvant regimen consisting of Docetaxel + Cisplatin + S-1 (DCS) in patients with locoregionally advanced unresectable gastric adenocarcinoma characterized by tumors with bulky regional lymph nodes (T1–4a, N-bulky, M0) or T4b tumors (any N, M0)).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included 78 patients with locoregionally advanced gastric adenocarcinoma treated at a university hospital in Vietnam, comprising 47 retrospective and 31 prospective cases. Patients received 2 - 4 cycles of DCS chemotherapy, with each cycle comprising intravenous docetaxel (35 mg/m²) and cisplatin (35 mg/m²) on days 1 and 15, and oral S-1 (40 mg/m²/twice daily) from days 1 to 14, repeated every 4 weeks. Clinical treatment response was assessed after every three cycles and re-staging evaluation by using the RECIST criteria and contrast-enhanced CT scans after 2 - 4 cycles, depending on patient response and tolerability. Patients with a good response and down-staging were referred for gastrectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age was 58 years, and 64.1% were male. Following neoadjuvant chemotherapy, the proportion of T4b tumors decreased from 78.2% to 52.6%, while T4a tumors increased from 20.5% to 43.6%. The rate of N-bulky decreased from 23.1% to 11.5%. Anemia and neutropenia were the most common hematological toxicities, predominantly grade 1–2. Gastrointestinal toxicity and hair loss were the most frequent clinical adverse events, mostly grade 1–2. Among 65 patients (83.3%) achieving an objective response to neoadjuvant chemotherapy, 42 (53.8%) underwent gastrectomy, with R0 resection achieved in 92.9%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Neoadjuvant chemotherapy using the DCS regimen every 4 weeks demonstrated high effectiveness and safety in patients with locoregionally advanced unresectable gastric adenocarcinoma characterized by extensive regional metastases, and increased their eligibility for successful gastrectomy (R0 resection).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>This study is a retrospective and prospective cohort study, not a clinical trial.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"659-669"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145342877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Affecting Quality Control (QC) Failure Rates in Somatic Breast Cancer (BRCA) Gene Testing in Castrate Resistant Prostate Cancer: Experiences From an Australian Cancer Care Centre","authors":"Cian O'Leary,&nbsp;Edward Yoong,&nbsp;Admire Matsika,&nbsp;Niara Oliveira","doi":"10.1111/ajco.70011","DOIUrl":"10.1111/ajco.70011","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Castrate-resistant prostate cancer (CRPC) is a common malignancy with poor prognostic outcomes. Breast cancer <i>(BRCA</i>) genes 1 and 2 mutations occur in prostate cancers and confer poorer prognoses. Somatic <i>BRCA</i> testing can lead to inconclusive results, which can gatekeep patients from accessing targeted medications. We assessed the somatic <i>BRCA</i> testing results among our cohort of CRPC patients for factors contributing to quality control (QC) failures and inconclusive testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective review of the records of all patients with CRPC attending our cancer care centers from 2020 to 2023. We identified the presence/absence of somatic <i>BRCA</i> testing results on their record. For those with returned results, we collected key information including biopsy characteristics, time from biopsy to <i>BRCA</i> result, and outcome of <i>BRCA</i> testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 147 patients with CRPC attended our service between January 2020 and 2023. A total of 54 patients (40%) had somatic <i>BRCA</i> testing performed on a tumor biopsy sample. A total of 35 somatic tests (65%) returned an actionable (positive or negative) result. The remaining 19 (35%) returned as inconclusive/QC failures. QC failures were significantly associated with a greater time from initial biopsy to somatic testing result (60 vs. 27 months, <i>p</i> = 0.033). The type of tissue biopsied, tumor percentage in biopsy sample, tissue sampling method, and sampling hospital did not contribute significantly to QC failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A longer tissue retention interval from biopsy to somatic <i>BRCA</i> testing is associated with a greater risk of inconclusive test results. We recommend a repeat biopsy for <i>BRCA</i> testing in CRPC patients where archival tissue is older than 5 years.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"640-645"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Limited-Margin Radiotherapy Change the Recurrence Pattern and Survival of Patients With IDH-Wild–Type Glioblastoma? Analysis and Validation of a Different Approach","authors":"Volkan Semiz,&nbsp;Oguz Cetinayak,&nbsp;Barbaros Aydın,&nbsp;Seyda Kınay,&nbsp;Dogukan Akcay,&nbsp;Nuri Karabay,&nbsp;Fadime Akman Can","doi":"10.1111/ajco.70014","DOIUrl":"10.1111/ajco.70014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>We aimed to analyze our radiotherapy protocol by evaluating its effect on recurrence patterns and survival outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We assessed 69 patients diagnosed with IDH-wild–type glioblastoma who underwent chemoradiotherapy at our institution from January 2014 to January 2021. A high-risk clinical target volume (CTV_high) was created with a 1 cm margin in all directions from the GTV, while a low-risk clinical target volume (CTV_low) was established with a 2 cm margin. Planned treatment volumes with a 2–3 mm margin in all directions were created, and doses of 60 and 50 Gy were prescribed in 30 fractions. Recurrence patterns were classified as central, in-field, marginal, or distant based on the 60 and 50 Gy D95 isodose lines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>With a median follow-up of 21 months, 88.4% of patients experienced recurrence. The overall survival rates at 1, 2, and 5 years were 84.1%, 51.5%, and 17%, respectively. The progression-free survival rates at the same intervals were 44.9%, 21.5%, and 9.5%, respectively. Recurrence patterns were central in 63.9%, in-field in 18%, marginal in 4.9%, and distant in 13.1%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The recurrence pattern remained unchanged with our protocol. With longer survival times, distant recurrence rates increase, yet central and in-field recurrences remain dominant. Despite the decrease in the volume that received the 60 Gy dose, marginal recurrences remained at a notably low level.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"646-653"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145028873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Real-World Results From an Early Access Program in Malaysia","authors":"Fuad Bin Ismail,&nbsp;Mohamed Ibrahim Abdul Wahid,&nbsp;Muthukkumaran Thiagarajan,&nbsp;Ai Lian Tan,&nbsp;Nellie Lay Chin Cheah,&nbsp;Kai Seng Lam,&nbsp;Doris Sze Ying Chow,&nbsp;Soo Fan Ang,&nbsp;Michelle Ng,&nbsp;Hannah Loke,&nbsp;John Seng Hooi Low","doi":"10.1111/ajco.70042","DOIUrl":"10.1111/ajco.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Avelumab first-line (1L) maintenance was approved for treatment of advanced urothelial carcinoma (UC) based on results from the JAVELIN Bladder 100 Phase 3 trial. We report real-world data from an early access program (EAP) for avelumab 1L maintenance treatment in Malaysia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from patients with locally advanced or metastatic UC who received ≥ 1 dose of avelumab 1L maintenance treatment between September 2021 and January 2023 were obtained retrospectively. Patient and treatment characteristics, best response to treatment, and safety were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data were provided from 13 patients treated at 9 hospitals in Malaysia. Seven patients (53.8%) were female, and ECOG performance status prior to 1L chemotherapy was 0–1 in 11 patients (84.6%) and 2 in 2 patients (15.4%). Chemotherapy included cisplatin in 6 patients (46.2%) and carboplatin in 7 patients (53.8%), and the best response was complete response in 1 patient (7.7%), partial response in 7 patients (53.8%), and stable disease in 5 patients (38.5%). The median duration of avelumab treatment was 9 months, with treatment ongoing in 4 patients (30.8%) at last follow-up. The objective response rate was 30.8% and an additional 5 patients (38.5%) had stable disease as the best response. Median PFS was 10.4 months. Reasons for discontinuation were disease progression in 8 patients (61.5%) and patient withdrawal in 1 patient (7.7%). Treatment-related adverse events occurred in 3 patients (23.1%) and were grade 2 in 1 patient (7.7%) and grade 1 in 2 (15.4%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Data from this small EAP population support the use of avelumab 1L maintenance treatment in patients with advanced UC in Malaysia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"744-748"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145538803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Breast and Gynecological Cancer: A Review of Systematic Reviews, 1985–2025","authors":"Fatma Qurrotunnada,&nbsp;Erna Rochmawati","doi":"10.1111/ajco.70052","DOIUrl":"10.1111/ajco.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Breast and gynecological cancers can significantly impact patients’ quality of life (QoL), which has become an important outcome measure in cancer care. This review aims to provide an updated synthesis of the literature on the QoL among patients with breast and gynecological cancers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A review of systematic reviews was conducted using PubMed, Scopus, Science Direct, and Wiley Online Library to identify papers from 1985 to 2025. Publications were screened following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and methodological quality was assessed using the A Measurement Tool to Assess Systematic Review (AMSTAR) criteria. The findings were summarized in tables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-four studies were selected for inclusion. Findings were summarized under the following themes: quality-of-life measurements; treatments (including exercise, therapy, and digital intervention); and QoL among different nations, races, and regions. The EORTC QLQ-C30 emerged as the most widely used assessment tool in cancer research. Most reviews focused on the impact of treatments. According to the reviews, aerobic exercise, Baduanjin exercise, and acupuncture were the top recommended interventions for improving QoL in patients with breast cancer (BC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There are many perceived challenges to collecting the data. Most of them involve obstacles in reporting and a variety of designs, interventions, and outcomes, making it hard to identify the most effective methods for improving QoL. However, some interventions have been proven to be effective for BC patients, including aerobic and Baduanjin exercises, yoga, acupuncture, and cognitive-behavioral stress management. Randomized controlled trials are needed to validate and refine treatment protocols. Future systematic reviews and meta-analyses should follow the reporting guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"726-743"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “National Clinician Perspectives on Immunotherapy Toxicity: Informing Multidisciplinary Disciplinary Meetings in New Zealand”","authors":"","doi":"10.1111/ajco.70130","DOIUrl":"10.1111/ajco.70130","url":null,"abstract":"<p>2025 MOGA Annual Scientific Meeting PROGRAM and ABSTRACTS. <i>Asia-Pacific Journal of Clinical Oncology</i>, 21: 5–52. https://doi.org/10.1111/ajco.70008.</p><p>The spelling of the third author “Daymon Lo” is incorrect. This should be spelt “Danyon Lo.”</p><p>We apologize for this error.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148216229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of the Australian Guideline for the Management of Cancer Pain in Adults","authors":"Melanie R. Lovell,&nbsp;Farwa Rizvi,&nbsp;Tim Luckett,&nbsp;Meera Agar,&nbsp;Jane L. Phillips,&nbsp;Frances M. Boyle,&nbsp;John Stubbs,&nbsp;Tim Hucker,&nbsp;Roopa Gawarikar,&nbsp;Christina Abdel Shaheed,&nbsp;Jessica Lee,&nbsp;Aaron K. Wong,&nbsp;Jennifer Martin,&nbsp;Jennifer Philip","doi":"10.1111/ajco.70047","DOIUrl":"10.1111/ajco.70047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The Cancer Council Australia Cancer Pain Management in Adults Clinical Guideline aimed to inform timely, evidence-based guidance for managing cancer-related pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The ADAPTE approach for guideline updates was adopted. Source guidelines were selected following the AGREE II criteria. The target population was adults with chronic cancer-related pain. The interventions were screening, assessment, and management of cancer-related pain. Target users and settings were all health professionals caring for adults with cancer in any healthcare setting. Outcomes are reduction in cancer-related pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Recommendations were mostly adopted directly from source guidelines and the recommendation strength reflected those of the source guidelines. Those which were developed de novo were either based on Level 1 evidence or consensus within the context of a documented need in the Australian setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The Cancer Council Australia guideline for managing cancer pain in adults contains evidence-based recommendations to guide appropriate evidence-based care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"705-716"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Increasing Importance of Breast Cancer in the United Arab Emirates","authors":"Ruqaiyyah Siddiqui,&nbsp;Shaikha Alagroobi Alsuwaidi,&nbsp;Oktay Irkorucu,&nbsp;Malik Hassan Mehmood,&nbsp;Naveed Ahmed Khan","doi":"10.1111/ajco.70050","DOIUrl":"10.1111/ajco.70050","url":null,"abstract":"<p>Breast cancer is a ubiquitous health problem in the world, and recent studies point toward an increase in breast cancer incidence in the Middle East. The prevalence of breast cancer in the United Arab Emirates (UAE) has evidently increased dramatically throughout the decades, making breast cancer one of the most prevalent types of cancer. In addition, breast cancer is alarmingly being diagnosed at an earlier age, almost a decade younger in the UAE compared to Western regions. Several causative risk factors may be attributed to this increase, such as obesity caused by a developing sedentary lifestyle and consuming a high-caloric diet, genetic factors, and other relevant issues, including limited knowledge and awareness regarding breast cancer, low participation levels in breast cancer examinations, and lack of medical insurance coverage. Herein, we discuss the incidence of breast cancer, screening, risk factors, treatment, and cancer registry in the UAE. We also deliberate current advances in breast cancer diagnosis and treatment in the UAE, as well as relate breast cancer in the UAE with other Middle Eastern countries, such as Saudi Arabia, Kuwait, and Oman. Future clinical trials with a focus on the local population are encouraged, along with the establishment of a clinical trials unit that has a focus on cancer and breast cancer in particular, within the region.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"717-725"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70050","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives of the Use of Neoadjuvant Therapy in the Management of Locally Advanced and Locally Recurrent Colon Cancer: A Bi-National Survey of Colorectal Surgeons","authors":"Rathin Gosavi,&nbsp;Alexander Heriot,&nbsp;Vignesh Narasimhan,&nbsp;Satish K. Warrier","doi":"10.1111/ajco.70035","DOIUrl":"10.1111/ajco.70035","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Colorectal cancer is a significant global health burden, with locally advanced colon cancer (LACC) comprising up to 20% of cases and associated with high rates of local recurrence and distant metastases. Although neoadjuvant chemotherapy (NAC) is well established in several gastrointestinal malignancies, its role in LACC and locally recurrent colon cancer remains debated. This study aimed to assess the perceptions and current practices of colorectal surgeons in Australia and New Zealand regarding the use of neoadjuvant therapies in these settings.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A structured 16-question online survey was distributed via Qualtrics to 275 colorectal surgeons affiliated with the Colorectal Surgical Society of Australia and New Zealand (CSSANZ). The survey included demographic questions and 13 clinical scenarios addressing the management of LACC and locally recurrent colon cancer without distant metastases. Responses were collected over 1 month, with one reminder sent at 2 weeks. Data were analyzed using Microsoft Excel, and responses were presented as percentages with bar graphs illustrating management preferences.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Ninety-seven surgeons (35.3% response rate) completed the survey; 86% were based in Australia and 70% had more than 5 years of consulting experience. Overall, 57% of respondents had previously employed neoadjuvant chemotherapy ± radiotherapy for non-metastatic LACC. In T4N0 disease, 54.3% opted for upfront resection, while 46% favored neoadjuvant strategies (29.4% chemotherapy and 16.3% chemoradiotherapy). For T4N1/2 disease, 63.5% preferred neoadjuvant therapy. Management varied in more complex scenarios: in obstructing cecal cancers with retroperitoneal invasion, 75% favored upfront resection; in non-obstructing transverse colon cancers invading the liver and sigmoid cancers with bladder invasion, decisions were split between upfront surgery and neoadjuvant treatment. For locally recurrent cancers, the majority preferred upfront surgery in non-T4 cases (68.5%), whereas over half (56.5%) opted for neoadjuvant therapy for T4 recurrent disease, particularly when vascular structures were involved.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The survey reveals a paradigm shift among colorectal surgeons in Australia and New Zealand toward incorporating neoadjuvant therapies for managing LACC and locally recurrent colon cancer. While upfront resection remains standard of care, there is increasing adoption of neoadjuvant strategies to downstage tumors and potentially improve oncological outcomes. Further high","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"654-658"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions","authors":"Al-Yafie Shikaha Ahmed Y.,&nbsp;Lee Wei Shyn,&nbsp;Pong Ben Jun Xiang,&nbsp;Rajendran Dhanusha,&nbsp;Tesfagin Reem Michael,&nbsp;Wei Hsum Yap,&nbsp;Bey Hing Goh,&nbsp;Rebecca Shin-Yee Wong","doi":"10.1111/ajco.70038","DOIUrl":"10.1111/ajco.70038","url":null,"abstract":"<p>Hematologic malignancies are cancers that affect the bone marrow, lymphatic system, and hematopoietic cells, resulting in various cancer subtypes and clinical manifestations. Currently, tissue biopsy in hematological malignancies is typically performed for genomic profiling and has limitations such as invasiveness, lengthy procedures, and high expense. On the other hand, liquid biopsy serves as an emerging tool used for examining the blood or other bodily fluids of patients, for the purpose of identifying genetic mutations, biomarkers, or cancer-related substances. Liquid biopsy biomarkers include circulating tumor DNA (ctDNA), microRNA (miRNA), and exosomes. In the context of hematological malignancies, these biomarkers offer valuable insights into disease etiology, enabling effective disease monitoring and guiding treatment decisions owing to their differential expression patterns. This review critically examines the recent advancements and effectiveness of liquid biopsy biomarkers in the areas of diagnosis, therapy, and monitoring. The challenges and future directions of liquid biopsy for hematological malignancies are also discussed.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"670-684"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}